Chimeric antigen receptor T-cell therapy in patients with neurologic comorbidities

被引：11

作者：

Rubinstein, Jeremy D. ^{[1
,2
]}

Nelson, Adam S. ^{[1
,3
]}

Krupski, Christa ^{[1
,3
]}

O'Brien, William ^{[4
,5
]}

Taylor, J. Michael ^{[1
,6
]}

Badgett, Tom C. ^{[7
]}

Huang, Michael ^{[8
]}

Davies, Stella M. ^{[1
,3
]}

Phillips, Christine L. ^{[1
,2
]}

机构：

[1] Univ Cincinnati, Coll Med, Dept Pediat, Cincinnati, OH USA

[2] Cincinnati Childrens Hosp Med Ctr, Div Oncol, Canc & Blood Dis Inst, 3333 Burnet Ave,MLC 7015, Cincinnati, OH 45229 USA

[3] Cincinnati Childrens Hosp Med Ctr, Div Bone Marrow Transplantat & Immune Deficiency, Canc & Blood Dis Inst, Cincinnati, OH 45229 USA

[4] Univ Cincinnati, Coll Med, Dept Radiol, Cincinnati, OH USA

[5] Cincinnati Childrens Hosp Med Ctr, Dept Radiol & Med Imaging, Cincinnati, OH 45229 USA

[6] Cincinnati Childrens Hosp Med Ctr, Div Neurol, Cincinnati, OH 45229 USA

[7] Univ Kentucky, Dept Pediat, Coll Med, Lexington, KY USA

[8] Univ Louisville, Sch Med, Pediat Canc & Blood Disorders, Louisville, KY 40292 USA

来源：

PEDIATRIC BLOOD & CANCER | 2020年 / 67卷 / 04期

关键词：

CAR-T; cellular therapy; neurotoxicity; pre-B ALL; CYTOKINE RELEASE SYNDROME; NEUROTOXICITY; BIOMARKERS; CHILDREN;

D O I：

10.1002/pbc.28199

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Chimeric antigen receptor T cells (CAR-T) are an effective and potentially durable treatment for refractory and multiply relapsed B-cell acute lymphoblastic leukemia. Neurotoxicity is frequent after CAR-T cell therapy. Mechanisms driving neurotoxicity are incompletely understood, and symptoms can range from transient and mild to severe and life-threatening. Providers have exercised caution in providing CAR-T to patients with neurological comorbidities or extramedullary disease. Here, we report three patients with prior significant neurologic morbidity who safely tolerated CAR-T cell infusion after bridging therapy with conventional chemotherapy.

引用

页数：5

共 50 条

[21] Chimeric antigen receptor T-cell therapy in autoimmune diseases
Liu, Jie
Zhao, Yan
Zhao, Hai
FRONTIERS IN IMMUNOLOGY, 2024, 15
[22] Chimeric antigen receptor T-cell therapy for solid tumors
Newick, Kheng
Moon, Edmund
Albelda, Steven M.
MOLECULAR THERAPY-ONCOLYTICS, 2016, 3
[23] Chimeric antigen receptor T-cell therapy for breast cancer
Gharghani, Mighmig Simonian
Simonian, Miganoosh
Bakhtiari, Faezeh
Ghaffari, Mozhan Haji
Fazli, Ghazaleh
Bayat, Ali Ahmad
Negahdari, Babak
FUTURE ONCOLOGY, 2021, 17 (22) : 2961 - 2979
[24] First Chimeric Antigen Receptor T-Cell Therapy Approved
Brower, Vicki
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2017, 109 (11):
[25] Chimeric Antigen Receptor T-Cell Therapy for Multiple Myeloma
Hosen, Naoki
CANCERS, 2019, 11 (12)
[26] Chimeric antigen receptor T-cell therapy for multiple myeloma
Wang, Zehua
Chen, Chen
Wang, Lei
Jia, Yongxu
Qin, Yanru
FRONTIERS IN IMMUNOLOGY, 2022, 13
[27] Chimeric Antigen Receptor T-Cell Therapy for Colorectal Cancer
Sur, Daniel
Havasi, Andrei
Cainap, Calin
Samasca, Gabriel
Burz, Claudia
Balacescu, Ovidiu
Lupan, Iulia
Deleanu, Diana
Irimie, Alexandru
JOURNAL OF CLINICAL MEDICINE, 2020, 9 (01)
[28] Chimeric antigen receptor T-cell therapy hits the market
Boyer, Michael W.
IMMUNOTHERAPY, 2018, 10 (11) : 911 - 912
[29] Chimeric antigen receptor T-cell therapy for multiple myeloma
Hosen, Naoki
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2020, 111 (04) : 530 - 534
[30] Mechanisms of failure of chimeric antigen receptor T-cell therapy
Li, Xiaoqing
Chen, Weihong
CURRENT OPINION IN HEMATOLOGY, 2019, 26 (06) : 427 - 433

← 1 2 3 4 5 →